Results 31 to 40 of about 25,343 (258)

Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome:therapeutic perspectives for 5-HT1A agonists [PDF]

, 2014
Rett syndrome is a neurological disorder caused by loss of function of methyl-CpG-binding protein 2 (MeCP2). Reduced function of this ubiquitous transcriptional regulator has a devastating effect on the central nervous system.
Abdala, Ana Paula, Bissonnette, John, Newman-Tancredi, Adrian   +2 more
core   +3 more sources

Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment

Biomedicines, 2023
Mitophagy is an important process that participates in mitochondrial quality control. Dysfunctions in this process can be caused by mutations in genes like PRKN and are associated with the development and progression of Parkinson’s Disease (PD). The most
Ana Gabrielle Bispo, Caio S. Silva, Camille Sena-dos-Santos, Dafne Dalledone Moura, Brenda Hanae Bentes Koshimoto, Bruno Lopes Santos-Lobato, Ândrea Ribeiro-dos-Santos, Giovanna C. Cavalcante   +7 more
doaj   +1 more source

Episodic neurologic disorders: syndromes, genes, and mechanisms. [PDF]

, 2013
Many neurologic diseases cause discrete episodic impairment in contrast with progressive deterioration. The symptoms of these episodic disorders exhibit striking variety.
Fu, Ying-Hui, Ptáček, Louis J, Russell, Jonathan F   +2 more
core   +2 more sources

An update on adenosine A2A receptors as drug target in Parkinson's disease [PDF]

, 2015
Adenosine receptors are G protein-coupled receptors (GPCRs) that mediate the physiological functions of adenosine. In the central nervous system adenosine A2A receptors (A2ARs) are highly enriched in striatopallidal neurons where they form functional ...
Arnau de Bolós, Josep M., Ciruela Alférez, Francisco, Fernández Dueñas, Víctor, Pedrós, Consuelo, Vallano Ferraz, Antonio   +4 more
core   +2 more sources

Fluphenazine decanoate (depot) and enanthate for schizophrenia [PDF]

, 2015
Background: Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance.
Abuzzahab, Abuzzahab, Abuzzahab, Adamson, Ahlfors, Alarcon, Alarcon, Albert, Altamura, Altamura, Altman, Andreasen, Andreasen, Angst, Angst, Arato, Asarnow, Asberg, Astrup, Balon, Bankier, Bao, Barnes, Barnes, Barnes, Barsa, Bastie, Benassi, Berliner, Bilone, Bland, Bloch, Boissel, Boyer, Breier, Buck, Caranza, Carpenter, Carpenter, Carpenter, Cassady, Chacon, Chacon, Charalampous, Chein, Chien, Childers, Chouinard, Chouinard, Chouinard, Chouinard, Chouinard, Chouinard, Chowdhury, Clark, Cohen, Cole, Cookson, Cookson, Coufal, Crawford, Curry, Curry, Curson, Curson, David, David, Davis, Dencker, Dencker, Dencker, Dencker, Dencker, Dencker, Dengler, DeWolfe, Divine, Donlon, Donlon, Donlon, Donlon, Donner, Doongaji, Dossenbach, Dotti, Downing, Egger, Elbourne, Endicott, Engelhardt, Engstrand, Fallon, Falloon, Faltus, Faretra, Feighner, Feng, Filip, Floru, Floru, Frangos, Furukawa, Gelenberg, Giannelli, Gillis, Gitlin, Gitlin, Giudice, Goff, Goldberg, Goldberg, Goldberg, Goldberg, Goldstein, Gopalakrishnan, Grosser, Gulliford, Guy, Haider, Hall, Hamilton, Hanlon, Harper, Haslam, Haynes, Heinrich, Held, Higgins, Hirsch, Hirsch, Hirsch, Hirsch, Hirsch, Hirsch, Hogarty, Hogarty, Hogarty, Holden, Holt, Honigfeld, Hsu, Hutton, Inderbitzin, Inderbitzin, Ionescu, Iqbal, Irwin, Itil, Itil, Itil, Itil, Jablensky, Jain, Jakovljevic, James, Javed, Johnson, Jolley, Jones, Ju, Jue, Kabes, Kabes, Kabes, Kabes, Kane, Kane, Kane, Kane, Kane, Kane, Kane, Kane, Kaneno, Kay, Kelly, Kenway, Keskiner, Keskiner, Keskiner, Khazaei, Khazaie, King, Kinon, Kinross-Wright, Kissling, Knights, Kong, Krawiecka, Kreisman, Kurland, Kurland, Landmark, Lapierre, Lapierre, Lapierre, Lapierre, Lasky, Leff, Leff, Lehmann, Leong, Leucht, Leucht, Levenson, Levine, Levinson, Levinson, Levinson, Lewis, Lewis, Lingjaerde, Litman, Ljubin, Lundin, Lundin, MacCrimmon, Magnus, Magnus, Mahmoud, Malm, Mandel, Marder, Marder, Marder, Marder, Marder, Marder, Marder, Marder, Marder, Marder, Marder, Marshall, Martenyi, Martin, Mattes, McClelland, McCreadie, McCreadie, McCreadie, McCreadie, McKane, McLaren, Meco, Mimica, Moher, Montejo, Morris, National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group, Nestoros, Odejide, Overall, Owen, Palma Wenzel, Pichot, Pickar, Pickar, Pickar, Pinto, Pollack, Praag, Praag, Preussler, Preussler, Putten, Putten, Quitkin, Quitkin, Quitkin, Ravanic, Ravaris, Ravaris, Rifkin, Rifkin, Rifkin, Rifkin, Rifkin, Roose, Rossger, Rossi, Russell, Schausberger, Schipper, Schlosberg, Schneider, Schooler, Schooler, Schooler, Schooler, Schooler, Schooler, Schooler, Schubert, Schünemann, Shafti, Sharma, Shenoy, Shepherd, Shu, Simon, Simpson, Simpson, Singh, Song, Steingard, Stevens, Stevens, Tegeler, Tran, Tretreault, Tsai, Tsai, Turner, Turner, Ukoumunne, Ushakov, Ushakov, Verster, Vestre, Viala, Villeneuve, Vinar, Walker, Weiden, Wiles, Winter, Wistedt, Wistedt, Wistedt, Wistedt, Wistedt, Wistedt, Wistedt, Woggon, Xia, Zapletalek   +336 more
core   +1 more source

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications [PDF]

, 2017
The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonergic (5-HT) system has been long established and has received increased attention during the last decade.
Benazzouz, Abdelhamid, De Deurwaerdère, Philippe, Miguélez Palomo, Cristina, Ugedo Urruela, Luisa   +3 more
core   +2 more sources

Clinical Management of Drug Induced Dyskinesia in Parkinson's Disease: Why Current Approaches May Need to Be Changed to Optimise Quality of Life [PDF]

European Medical Journal, 2016
Parkinson’s disease is a complex, progressive neurodegenerative disorder associated with both motor and non-motor symptoms. Current treatment strategies mainly target the alleviation of motor symptoms through dopaminergic replacement therapy.
Jean-Francois Daneault, Gloria Vergara-Diaz, Sunghoon Ivan Lee   +2 more
doaj  

Disminución de las discinesias en un modelo de Parkinson en ratas Wistar, mediada por el fitofármaco Mucuna pruriens

Neurology Perspectives, 2021
Resumen: La enfermedad de Parkinson (EP) es una enfermedad neurodegenerativa cuyo tratamiento sintomático más eficaz es la L-dopa, sin embargo, puede inducir discinesias (DIL).
J.C. Guzman, C.A. Otalora, P. Caro, E.L. Mayorga, J.P. Alcazar, L.F. Turner   +5 more
doaj   +1 more source

Tardive Dyskinesia in Relation to Estimated Dopamine D2 Receptor Occupancy in Patients with Schizophrenia: Analysis of the CATIE data [PDF]

, 2014
Objective The objective of this study was to evaluate the relationship between antipsychotic-induced tardive dyskinesia (TD) and estimated dopamine D2 receptor occupancy levels in patients with schizophrenia, using the dataset from the Clinical ...
Bies, Robert R., Mimura, Masaru, Mizuno, Yuya, Pollock, Bruce G., Remington, Gary, Suzuki, Takefumi, Uchida, Hiroyuki, Yoshida, Kazunari   +7 more
core   +2 more sources

Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia

Neuropsychiatric Disease and Treatment, 2020
Tadesse Misgana,1 Niguse Yigzaw,2 Getachew Asfaw3 1Department of Psychiatry, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia; 2Department of Psychiatry, College of Medicine and Health Science, University of Gondar, Gondar ...
Misgana T, Yigzaw N, Asfaw G
doaj